Article

Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
Microdrops show promise for safer retinopathy of prematurity screening in preterm infants
January 3rd 2025

Microdrops show promise for safer retinopathy of prematurity screening in preterm infants

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Strabismus in animation: study highlights harmful stereotypes in children's films
November 28th 2024

Strabismus in animation: study highlights harmful stereotypes in children's films

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

NIH highlights 5 key elements of cortical visual impairment (CVI)
November 23rd 2024

NIH highlights 5 key elements of cortical visual impairment (CVI)

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease
November 18th 2024

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease

© 2025 MJH Life Sciences

All rights reserved.